DR. SCOTT A TOMLINS, M.D., PH.D.
Medical Practice in Ann Arbor, MI
License number
Michigan 4301094170
Category
Medical Practice
Type
Anatomic Pathology
Address
Address
1500 Floor University Hospital Recp Pathology, Ann Arbor, MI 48109
Phone
(800) 862-7284
(734) 936-2047
(734) 936-2047
Personal information
See more information about SCOTT A TOMLINS at radaris.comName
Address
Phone
222 Brookridge Ct, Ann Arbor, MI 48103
1077 Barton Dr, Ann Arbor, MI 48105
222 Brookridge Ct, Ann Arbor, MI 48103
Professional information
Spink1 As A Prostate Cancer Marker And Uses Thereof
US Patent:
2010012, May 27, 2010
Filed:
Nov 8, 2007
Appl. No.:
12/513637
Inventors:
Arul M. Chinnaiyan - Plymouth MI, US
Scott A. Tomlins - Ann Arbor MI, US
Daniel R. Rhodes - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
Scott A. Tomlins - Ann Arbor MI, US
Daniel R. Rhodes - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 6, 435 71
Abstract:
Compositions and methods for cancer research, diagnosis, and treatment, including but not limited to, cancer markers are provided. In particular, SPINK1 and other markers for prostate cancer are provided.
Scott Arthur Tomlins, Ann Arbor MI
Specialties:
Pathology, Anatomic Pathology, Clinical Pathology
Work:
U of M Pathology
1500 E Medical Center Dr, Ann Arbor, MI 48109
1500 E Medical Center Dr, Ann Arbor, MI 48109
Education:
University of Michigan Medical School (2009)
Dr. Scott Tomlins, Ann Arbor MI - MD (Doctor of Medicine)
Specialties:
Anatomic & Clinical Pathology
Address:
1500 E Medical Center Dr SUITE 5054, Ann Arbor 48109
(800) 862-7284 (Phone), (734) 615-2964 (Fax)
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Center Dr SUITE 2ND, Ann Arbor 48109
(800) 211-8181 (Phone), (800) 826-7284 (Fax)
1301 Catherine St, Ann Arbor 48109
(734) 764-3270 (Phone)
(800) 862-7284 (Phone), (734) 615-2964 (Fax)
REGENTS OF THE UNIVERSITY OF MICHIGAN
1500 E Medical Center Dr SUITE 2ND, Ann Arbor 48109
(800) 211-8181 (Phone), (800) 826-7284 (Fax)
1301 Catherine St, Ann Arbor 48109
(734) 764-3270 (Phone)
Languages:
English
Education:
Medical School
University of Mi Med Sch
Graduated: 2005
University of Mi Med Sch
Graduated: 2005
Transgenic Animals Comprising Gene Fusions
US Patent:
2010025, Oct 7, 2010
Filed:
Feb 21, 2007
Appl. No.:
11/708858
Inventors:
Chinnaiyan Arul - Plymouth MI, US
Bharathi Laxman - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Rohit Mera - Ann Arbor MI, US
Bharathi Laxman - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Rohit Mera - Ann Arbor MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
A01K 67/027
US Classification:
800 10, 800 13, 800 18
Abstract:
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusion nucleic acids and transgenic animals comprising recurrent gene fusion nucleic acids.
Methods And Compositions For Diagnosing Bladder Cancer
US Patent:
2010027, Nov 4, 2010
Filed:
May 3, 2010
Appl. No.:
12/772429
Inventors:
Arul Chinnaiyan - Plymouth MI, US
Rou Wang - Ann Arbor MI, US
David Morris - Gallatin TN, US
Scott Tomlins - Ann Arbor MI, US
Rou Wang - Ann Arbor MI, US
David Morris - Gallatin TN, US
Scott Tomlins - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to genes and gene panels as diagnostic markers and clinical targets for bladder cancer. Methods, compositions, and kits for diagnosing, determining, and determining risk of tumor aggressiveness are disclosed.
Recurrent Gene Fusions In Prostate Cancer
US Patent:
8211645, Jul 3, 2012
Filed:
Dec 30, 2009
Appl. No.:
12/650164
Inventors:
Scott Tomlins - Ann Arbor MI, US
Daniel Rhodes - Ann Arbor MI, US
Arul Chinnaiyan - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
Mark A. Rubin - New York NY, US
Xiao-Wei Sun - New York NY, US
Sven Perner - Ellwaugen, DE
Charles Lee - Marlborough MA, US
Francesca Demichelis - New York NY, US
Daniel Rhodes - Ann Arbor MI, US
Arul Chinnaiyan - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
Mark A. Rubin - New York NY, US
Xiao-Wei Sun - New York NY, US
Sven Perner - Ellwaugen, DE
Charles Lee - Marlborough MA, US
Francesca Demichelis - New York NY, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
The Brigham and Women's Hospital - Boston MA
The Brigham and Women's Hospital - Boston MA
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/04
US Classification:
435 612, 435 912, 435810, 536 221, 536 243
Abstract:
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Recurrent Gene Fusions In Prostate Cancer
US Patent:
8580509, Nov 12, 2013
Filed:
May 30, 2012
Appl. No.:
13/483176
Inventors:
Scott Tomlins - Ann Arbor MI, US
Daniel Rhodes - Ann Arbor MI, US
Arul Chinnaiyan - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
Mark A. Rubin - New York NY, US
Xiao-Wei Sun - New York NY, US
Sven Perner - Ellwaugen, DE
Charles Lee - Marlborough MA, US
Francesca Demichelis - New York NY, US
Daniel Rhodes - Ann Arbor MI, US
Arul Chinnaiyan - Ann Arbor MI, US
Rohit Mehra - Ann Arbor MI, US
Mark A. Rubin - New York NY, US
Xiao-Wei Sun - New York NY, US
Sven Perner - Ellwaugen, DE
Charles Lee - Marlborough MA, US
Francesca Demichelis - New York NY, US
Assignee:
The Regents of The University of Michigan - Ann Arbor MI
The Brigham and Women's Hospital, Inc. - Boston MA
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/02, C07H 21/04
US Classification:
435 612, 435 912, 435810, 536 221, 536 243
Abstract:
Recurrent gene fusions of androgen regulated genes and ETS family member genes in prostate cancer are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Recurrent Gene Fusions In Prostate Cancer
US Patent:
2009020, Aug 20, 2009
Filed:
Jul 6, 2007
Appl. No.:
11/825552
Inventors:
Arul M. Chinnaiyan - Plymouth MI, US
Scott Tomlins - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Assignee:
Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided.
Mipol1-Etv1 Gene Rearrangements
US Patent:
2011002, Feb 3, 2011
Filed:
Jul 3, 2008
Appl. No.:
12/667819
Inventors:
Arul M. Chinnaiyan - Plymouth MI, US
Scott Tomlins - Ann Arbor MI, US
Saravana Mohan Dhanasekaran - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Saravana Mohan Dhanasekaran - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
C40B 30/04, C12Q 1/68
US Classification:
506 9, 435 6
Abstract:
Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed.
Spink1 Targeted Therapy
US Patent:
2011020, Aug 25, 2011
Filed:
Feb 9, 2011
Appl. No.:
13/023694
Inventors:
Arul M. Chinnaiyan - Plymouth MI, US
Bushra Ateeq - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Bushra Ateeq - Ann Arbor MI, US
Scott Tomlins - Ann Arbor MI, US
Assignee:
The Regents of The University of Michigan - Ann Arbor MI
International Classification:
A61K 39/395, C12N 5/071, C12N 5/09, A61P 35/00, C07K 16/18
US Classification:
4241721, 435375, 5303898
Abstract:
The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to SPINK1 as a clinical target for prostate cancer.